Abstract | OBJECTIVE: METHODS: RESULTS: ITIH4 was downregulated in RA patients (151.1 (interquartile range (IQR): 106.2-213.5) ng/mL) than in HCs (306.8 (IQR: 238.9-435.1) ng/mL) (p < 0.001). Furthermore, ITIH4 was negatively related to C-reactive protein (CRP) (rs = -0.358, p < 0.001) and 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) (rs = -0.253, p = 0.014) in RA patients, but not correlated with other clinical features (all p > 0.05). Besides, ITIH4 was negatively linked with TNF-α (rs = -0.337, p = 0.001), IL-6 (rs = -0.221, p = 0.033), and IL-17A (rs = -0.368, p < 0.001) in RA patients, but not correlated with IL-1β (rs = -0.195, p = 0.061). Moreover, ITIH4 was gradually elevated in RA patients from baseline to W12 after treatment (p < 0.001). Additionally, the increment of ITIH4 at W6 and W12 was linked with treatment response and remission in RA patients (all p < 0.05). CONCLUSION: Circulating ITIH4 possesses clinical utility in monitoring disease risk, inflammation, disease activity, and treatment outcomes of RA.
|
Authors | Kejian He, Sanshan He, Min Su |
Journal | Journal of clinical laboratory analysis
(J Clin Lab Anal)
Vol. 36
Issue 3
Pg. e24231
(Mar 2022)
ISSN: 1098-2825 [Electronic] United States |
PMID | 35064701
(Publication Type: Journal Article)
|
Copyright | © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. |
Chemical References |
- Alpha-Globulins
- Biomarkers
- Tumor Necrosis Factor-alpha
- inter-alpha-inhibitor
|
Topics |
- Alpha-Globulins
- Arthritis, Rheumatoid
- Biomarkers
- Blood Sedimentation
- Humans
- Treatment Outcome
- Tumor Necrosis Factor-alpha
|